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Dura Mater Graft-Associated Creutzfeldt-Jakob Disease: The First 
Case in Korea
Since 1987, dura mater graft-associated iatrogenic Creutzfeldt-Jakob disease (dCJD) has 
been reported in many countries. We report the first case of dCJD in Korea. A 54-yr-old 
woman, who underwent resection of the meningioma in the left frontal region and 
received a dura mater graft 23 yr ago presented with dysesthesia followed by psychiatric 
symptoms and ataxia. Her neurological symptoms rapidly progressed to such an extent 
that she exhibited myoclonus, dementia, and pyramidal and extrapyramidal signs within  
8 weeks. The 14-3-3 protein was detected in her cerebrospinal fluid; however, an 
electroencephalogram did not reveal characteristic positive sharp wave complexes. 
Diffusion-weighted magnetic resonance images, obtained serially over 64 days, revealed 
the rapid progression of areas of high signal intensity in the caudate nucleus and cingulate 
gyrus to widespread areas of high signal intensity in the cortex and basal ganglia. 
Pathological examination of brain biopsy specimens confirmed the presence of spongiform 
changes and deposition of prion protein in the neurons and neuropils.
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INTRODUCTION
Creutzfeldt-Jakob disease (CJD) is a fatal, transmissible, neuro-
degenerative disorder that causes spongiform changes in the 
brain. CJD has 4 clinical forms: sporadic, genetic, iatrogenic, and 
variant. Sporadic and genetic CJD appear to occur in people from 
all countries and ethnic groups. Furthermore, to date, more than 
400 cases of iatrogenic CJD have been reported in 20 countries 
(1). No studies have reported cases of iatrogenic CJD in Korea. 
Iatrogenic CJD results from the inadvertent transmission of CJD 
during the course of medical or surgical treatment. The sources 
of infection reported in iatrogenic CJD were cadaveric dura ma-
ter grafts (2), human cadaveric pituitary hormone (3), corneal 
transplants (4), and neurosurgical equipment (5, 6). Since the 
first identification of dura mater graft-associated CJD (dCJD) in 
1987, almost 200 cases of dCJD have been identified worldwide 
(1). Here, we report the first case of dCJD in a patient in Korea, 
who had received a dura mater graft with Lyodura
® 23 yr ago.
CASE DESCRIPTION
A 54-yr-old woman was referred to a tertiary referral hospital 
because of ataxia and myoclonus in June 2010. She was diagnosed 
with meningioma in the left frontal area, and the meningioma 
was excised in 1987. One month before visiting the tertiary re-
ferral hospital, she first began experiencing general weakness 
and dysesthesia on the left side of her face and in the toes of her 
right foot. The findings of the brain magnetic resonance imag-
ing (MRI) (T1-weighted, T2-weighted, and FLAIR images with-
out diffusion-weighted images [DWIs]) performed at a neurol-
ogy outpatient clinic were not remarkable, except for encepha-
lomalacic changes that occurredas a sequela of brain surgery. Kim HL, et al.  •  Dura Mater-associated Creutzfeldt-Jakob Disease
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Subsequently, her neurological symptoms and signs progressed 
further to such an extent that she developed dysarthria and could 
not stand up without assistance. Immediately after admission 
to the tertiary referral hospital, she exhibited phobia, marked 
mood fluctuations, and insomnia. The first DWIs in the second 
MRI, performed 24 days after the first MRI, revealed slightly in-
creased signal intensity in the cingulate gyrus and caudate nu-
clei (Fig. 1). Discrete decreases in signal intensity were observed 
in the corresponding area in analog to digital converter aliasing 
(ADC) maps (data not shown), indicating reduced diffusivity. 
Five days after admission, she could not walk alone because of 
ataxia. Ten days after admission, she exhibited multifocal gen-
eralized myoclonus without seizures. During the next 2 weeks, 
her motor symptoms worsened further to such an extent that 
she developed anarthria and severe dysphagia. The higher cor-
tical function test could not be performed because she could 
not speak. However, she could understand simple commands 
and was partially communicable. She complained of fear due 
to visual hallucinations and diplopia. The third follow-up MRI, 
performed 1 month after the second one, revealed areas of in-
creased signal intensity in the right and left basal ganglia, insular 
cortex, primary motor cortex, and right and left medial frontal 
cortex (Fig. 1). One and a half months after the initial admission, 
she was confined to bed with frequent myoclonus. Her mental 
status had changed to a drowsy or stuporous state, and she slept 
during most of the day. An electroencephalogram (EEG) revealed 
moderate diffuse slowing of background activity without peri-
odic sharp wave complexes. The 14-3-3 protein was detected in 
her cerebrospinal fluid. There was no mutation in PRNP, and 
the genotype of codon 129 was methionine homozygote. She 
was tentatively diagnosed with CJD and referred to our CJD sur-
veillance center for confirmative diagnosis. A careful review of 
her past medical records revealed that Lyodura
® had been used 
to repair her dura in 1987. The fourth MRI, performed 1 month 
after the third MRI, revealed a high signal intensity lesion in both 
basal ganglia, both insulae, and the right and left frontotempo-
roparietal cortices (Fig. 1). A brain needle biopsy was performed 
at the right frontal region. Hematoxylin and eosin staining of bi-
opsy specimens revealed neuronal loss and astrocytosis with 
spongiform changes (Fig. 2). Immunostaining with a monoclo-
nal antibody (1C5) against prion protein revealed deposition of 
prion protein in the peri- and intraneuronal areas. We did not 
observe florid plaques in the biopsy specimens. The patient was 
discharged from the hospital to receive supporting treatment. 
She died after an overall disease course of 3 months.
DISCUSSION
To date, nearly 200 cases of iatrogenic dCJD have been reported 
worldwide (1). In this patient, CJD, confirmed by examination 
of brain biopsy specimens, was related to a dura mater graft. She 
underwent a dura mater graft performed using Lyodura
®, a brand 
of dura mater linked to an ongoing international outbreak of 
most of the reported cases of dCJD (1, 2). In this patient, the la-
tent period between Lyodura
® grafting and the onset of CJD was 
23 yr, which is within the range observed in the reported cases 
Fig. 1. Serial DWIs taken during the course of dCJD. The first DWI (left column), taken 
almost 6 weeks after her first neurological symptoms, revealedslightly increased signal 
intensity in the cingulate gyrus and the caudate nucleus. In the second DWI (middle 
column), taken 10 weeks after her first neurological symptoms, high signal intensity 
in both insulae, the caudate nucleus, and the medial frontal cortical region became 
obvious. In the third DWI (right column), taken 12 weeks after her first neurological 
symptoms, extensive high signal intensity was observed in the both basal ganglia and 
the cortex. 
Fig. 2. Microscopic findings. (A) Neuronal loss and spongiform change (hematoxylin and eosin stain). (B) Astrocytosis detected using an anti-GFAP antibody. (C) Deposition of 
prion protein monoclonal antibody (1C5) for prion protein (arrow).
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of dCJD (16 months-31 yr) (1, 7-11).
  More than 50% of the cases of dCJD have been identified in 
Japan. dCJD constitutes 6.2% of all CJD cases reported in Japan, 
and 135 cases of dCJD have been reported since November 2009 
(12). However, this is the first case of iatrogenic dCJD in Korea. 
The estimated risk for dCJD after exposure to human dura ma-
ter was reported to be 1 per 500 to 2000, depending on the study 
population and the year when the dura mater graft was per-
formed (8, 13, 14). However, an accurate estimation of the use 
of human dura mater grafts in Korea is not available.
  Studies have suggested that ataxia and psychiatric symptoms 
or signs are among the earliest symptoms of dCJD and are fol-
lowed by visual symptoms, dementia, myoclonus, and extrapy-
ramidal or pyramidal signs (7-9, 11). The clinical course of our 
patient followed this pattern. The MRI findings in our case re-
sembled those observed in sporadic CJD in other studies (7-9, 
11). We were able to review serial MR images obtained 4 times 
over 64 days when the patient was transferred to our center. While 
she was symptomatic, the areas of high signal intensity on DWIs 
progressed rapidly from suspicious changes in the cingulate gy-
rus and caudate nucleus to extensive cortical and basal ganglia 
involvement. Given the long latency of dCJD, the occurrence of 
these MRI changes within a short period in this case is remark-
able. 
  Although needle biopsy specimens may not represent the en-
tire brain, we believe that our patient presented with neuropatho-
logically non-plaque typed CJD (10). In a study of non-plaque 
type dCJD reported in Japan, all cases exhibited positive sharp 
wave complexes on EEG, unlike in our case (9). This might be 
explained by differences in the time between symptom onset 
and EEG investigation. In a Japanese non-plaque typedCJD se-
ries, a case with positive sharp wave complexes was detected 5 
months after symptom onset.However, the last EEG followup 
for our patient was 2.5 months after symptom onset. 
  In conclusion, we report the first case of dura mater-graft as-
sociated iatrogenic CJD in Korea. We observed a long incuba-
tion period in our patient, similar to that observed in other coun-
tries, and thus, iatrogenic CJD cases due to dura mater transplants 
still can be expected in the future.
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